Amicus Therapeutics, Inc. (FOLD)
USD 7.09
(-5.47%)
USD 7.09
(-5.47%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 427.65 Million USD | -13.62% |
| 2022 | 495.06 Million USD | 5.12% |
| 2021 | 470.96 Million USD | -0.58% |
| 2020 | 473.69 Million USD | 2.75% |
| 2019 | 461.01 Million USD | 14.59% |
| 2018 | 402.31 Million USD | 66.54% |
| 2017 | 241.57 Million USD | 34.82% |
| 2016 | 179.18 Million USD | 42.16% |
| 2015 | 126.04 Million USD | 80.35% |
| 2014 | 69.88 Million USD | 11.72% |
| 2013 | 62.55 Million USD | -12.32% |
| 2012 | 71.34 Million USD | -1.35% |
| 2011 | 72.32 Million USD | 27.42% |
| 2010 | 56.76 Million USD | -19.13% |
| 2009 | 70.18 Million USD | 19.11% |
| 2008 | 58.92 Million USD | 23.82% |
| 2007 | 47.58 Million USD | 1.56% |
| 2006 | 46.85 Million USD | 124.95% |
| 2005 | 20.83 Million USD | 336.53% |
| 2004 | -8.8 Million USD | -233.44% |
| 2003 | 6.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 98.25 Million USD | -15.55% |
| 2024 Q1 | 116.35 Million USD | 10.54% |
| 2023 Q2 | 102.77 Million USD | -11.94% |
| 2023 Q1 | 116.71 Million USD | -2.3% |
| 2023 Q4 | 105.26 Million USD | -1.02% |
| 2023 FY | 427.65 Million USD | -13.62% |
| 2023 Q3 | 106.35 Million USD | 3.48% |
| 2022 Q3 | 101.52 Million USD | -23.68% |
| 2022 Q2 | 133.03 Million USD | -5.68% |
| 2022 Q1 | 141.04 Million USD | -2.54% |
| 2022 FY | 495.06 Million USD | 5.12% |
| 2022 Q4 | 119.45 Million USD | 17.66% |
| 2021 Q3 | 106.96 Million USD | 0.11% |
| 2021 Q1 | 112.44 Million USD | -10.42% |
| 2021 Q4 | 144.71 Million USD | 35.3% |
| 2021 Q2 | 106.84 Million USD | -4.98% |
| 2021 FY | 470.96 Million USD | -0.58% |
| 2020 Q4 | 125.52 Million USD | 13.33% |
| 2020 Q1 | 131.09 Million USD | -4.12% |
| 2020 FY | 473.69 Million USD | 2.75% |
| 2020 Q2 | 106.3 Million USD | -18.91% |
| 2020 Q3 | 110.76 Million USD | 4.19% |
| 2019 Q1 | 109.88 Million USD | 13.07% |
| 2019 Q3 | 99.68 Million USD | -13.1% |
| 2019 Q4 | 136.72 Million USD | 37.15% |
| 2019 FY | 461.01 Million USD | 14.59% |
| 2019 Q2 | 114.71 Million USD | 4.39% |
| 2018 Q4 | 97.18 Million USD | -43.22% |
| 2018 Q2 | 64.8 Million USD | -6.3% |
| 2018 FY | 402.31 Million USD | 66.54% |
| 2018 Q1 | 69.16 Million USD | -8.39% |
| 2018 Q3 | 171.16 Million USD | 164.13% |
| 2017 Q1 | 50.83 Million USD | 1.22% |
| 2017 Q4 | 75.49 Million USD | 19.57% |
| 2017 Q3 | 63.13 Million USD | 21.17% |
| 2017 Q2 | 52.1 Million USD | 2.51% |
| 2017 FY | 241.57 Million USD | 34.82% |
| 2016 Q3 | 50.82 Million USD | 32.53% |
| 2016 Q4 | 50.21 Million USD | -1.19% |
| 2016 Q2 | 38.34 Million USD | -3.65% |
| 2016 FY | 179.18 Million USD | 42.16% |
| 2016 Q1 | 39.79 Million USD | -1.47% |
| 2015 FY | 126.04 Million USD | 80.35% |
| 2015 Q2 | 25.86 Million USD | 12.22% |
| 2015 Q4 | 40.39 Million USD | 9.95% |
| 2015 Q3 | 36.73 Million USD | 42.04% |
| 2015 Q1 | 23.04 Million USD | 7.27% |
| 2014 Q1 | 15.58 Million USD | 10.29% |
| 2014 Q4 | 21.48 Million USD | 21.43% |
| 2014 Q3 | 17.69 Million USD | 16.97% |
| 2014 Q2 | 15.12 Million USD | -2.91% |
| 2014 FY | 69.88 Million USD | 11.72% |
| 2013 Q3 | 15.17 Million USD | -5.19% |
| 2013 Q2 | 16 Million USD | -7.22% |
| 2013 FY | 62.55 Million USD | -12.32% |
| 2013 Q4 | 14.12 Million USD | -6.91% |
| 2013 Q1 | 17.25 Million USD | 8.34% |
| 2012 Q2 | 19.98 Million USD | 7.91% |
| 2012 FY | 71.34 Million USD | -1.35% |
| 2012 Q3 | 16.91 Million USD | -15.35% |
| 2012 Q4 | 15.92 Million USD | -5.87% |
| 2012 Q1 | 18.51 Million USD | -0.76% |
| 2011 Q4 | 18.66 Million USD | -1.44% |
| 2011 FY | 72.32 Million USD | 27.42% |
| 2011 Q1 | 15.96 Million USD | -8.55% |
| 2011 Q2 | 18.76 Million USD | 17.53% |
| 2011 Q3 | 18.93 Million USD | 0.9% |
| 2010 Q4 | 17.45 Million USD | 31.61% |
| 2010 FY | 56.76 Million USD | -19.13% |
| 2010 Q3 | 13.26 Million USD | 4.56% |
| 2010 Q2 | 12.68 Million USD | -4.97% |
| 2010 Q1 | 13.35 Million USD | -11.07% |
| 2009 Q4 | 15.01 Million USD | -18.36% |
| 2009 Q2 | 19.21 Million USD | 9.31% |
| 2009 Q1 | 17.57 Million USD | -8.57% |
| 2009 FY | 70.18 Million USD | 19.11% |
| 2009 Q3 | 18.38 Million USD | -4.29% |
| 2008 FY | 58.92 Million USD | 23.82% |
| 2008 Q4 | 19.22 Million USD | 48.4% |
| 2008 Q3 | 12.95 Million USD | -9.41% |
| 2008 Q2 | 14.29 Million USD | 14.86% |
| 2008 Q1 | 12.44 Million USD | -18.46% |
| 2007 Q2 | 10.28 Million USD | 0.51% |
| 2007 Q3 | 11.8 Million USD | 14.8% |
| 2007 Q4 | 15.26 Million USD | 29.32% |
| 2007 FY | 47.58 Million USD | 1.56% |
| 2007 Q1 | 10.23 Million USD | 188.31% |
| 2006 Q1 | -11.58 Million USD | -132.05% |
| 2006 FY | 46.85 Million USD | 124.95% |
| 2006 Q2 | -11.58 Million USD | 0.0% |
| 2006 Q3 | -11.58 Million USD | 0.0% |
| 2006 Q4 | -11.58 Million USD | 0.0% |
| 2005 Q3 | -4.99 Million USD | 0.0% |
| 2005 Q4 | -4.99 Million USD | 0.0% |
| 2005 Q1 | -4.99 Million USD | 0.0% |
| 2005 FY | 20.83 Million USD | 336.53% |
| 2005 Q2 | -4.99 Million USD | 0.0% |
| 2004 FY | -8.8 Million USD | -233.44% |
| 2003 FY | 6.6 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -55.378% |
| Alkermes plc | 996.24 Million USD | 57.074% |
| Agenus Inc. | 78.18 Million USD | -446.987% |
| Aptorum Group Limited | 10.56 Thousand USD | -4047325.705% |
| Ardelyx, Inc. | 169.93 Million USD | -151.653% |
| Dyadic International, Inc. | 9.15 Million USD | -4572.405% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1821.768% |
| Lantern Pharma Inc. | 17.87 Million USD | -2292.109% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -6252.563% |
| Novavax, Inc. | 779.12 Million USD | 45.111% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -427.56% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -420.282% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -2102.285% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1344.474% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -704.969% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -12.393% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1659.402% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1029.29% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1289.786% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -404.805% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2349.739% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -153.895% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1207.202% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -167.638% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 76.242% |
| AlloVir, Inc. | 180.93 Million USD | -136.359% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 4.058% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1340.776% |
| Bicycle Therapeutics plc | 216.92 Million USD | -97.145% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -148.776% |
| ChromaDex Corporation | 56.37 Million USD | -658.529% |
| Chimerix, Inc. | 93.38 Million USD | -357.924% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2974.493% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -184.086% |
| CRISPR Therapeutics AG | 463.49 Million USD | 7.733% |
| Precision BioSciences, Inc. | 92.46 Million USD | -362.51% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -68.337% |
| Fortress Biotech, Inc. | 200.19 Million USD | -113.617% |
| Fortress Biotech, Inc. | 200.19 Million USD | -113.617% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1205.964% |
| ImmuCell Corporation | 9.61 Million USD | -4346.656% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -170.984% |
| Immix Biopharma, Inc. | 16.14 Million USD | -2549.452% |
| Incyte Corporation | 1.19 Billion USD | 64.078% |
| Innoviva, Inc. | 132.15 Million USD | -223.6% |
| IO Biotech, Inc. | 91.44 Million USD | -367.669% |
| Jaguar Health, Inc. | 42.01 Million USD | -917.853% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -152.634% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -407.158% |
| ContextLogic Inc. | 387 Million USD | -10.504% |
| MiMedx Group, Inc. | 229.72 Million USD | -86.156% |
| MEI Pharma, Inc. | 34.78 Million USD | -1129.412% |
| NextCure, Inc. | 67.63 Million USD | -532.274% |
| Onconetix, Inc. | 34.9 Million USD | -1125.1% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -3255.178% |
| Opthea Limited | 191.96 Million USD | -122.773% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -15441.988% |
| Vaxcyte, Inc. | 468.04 Million USD | 8.63% |
| PDS Biotechnology Corporation | 43.04 Million USD | -893.492% |
| Precigen, Inc. | 84.18 Million USD | -408.014% |
| Pharming Group N.V. | 225.49 Million USD | -89.653% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -154.817% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -489.327% |
| PureTech Health plc | 144.59 Million USD | -195.754% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -228.298% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -74.439% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1659.402% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -87.008% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1285.823% |
| Acelyrin, Inc. | 422.06 Million USD | -1.324% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -3316566.667% |
| Summit Therapeutics Inc. | 87.68 Million USD | -387.707% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -1053.818% |
| Senti Biosciences, Inc. | 94.7 Million USD | -351.561% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -246.128% |
| Elevation Oncology, Inc. | 45.44 Million USD | -841.03% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1351.189% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -10748.447% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -223.549% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -1154.66% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -4960.36% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -135.879% |
| Seer, Inc. | 110.49 Million USD | -287.05% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -505.789% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -357.488% |
| ESSA Pharma Inc. | 32.13 Million USD | -1230.832% |
| GlycoMimetics, Inc. | 39.28 Million USD | -988.578% |
| GT Biopharma, Inc. | 13.57 Million USD | -3050.052% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -94.537% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -112.64% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -64.846% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -653.451% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -690.775% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -4203.343% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -5.969% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -2159.237% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -743.61% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -64.697% |
| Aptose Biosciences Inc. | 52.35 Million USD | -716.814% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -2867.661% |
| Soligenix, Inc. | 7.79 Million USD | -5386.045% |
| Century Therapeutics, Inc. | 56.07 Million USD | -662.696% |
| Kura Oncology, Inc. | 165.8 Million USD | -157.926% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -273.471% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -5040.654% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -17132.603% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -297.084% |
| Autolus Therapeutics plc | 196.72 Million USD | -117.384% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -405.157% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -267.231% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -2106.32% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -32.911% |
| GRI Bio, Inc. | 11.33 Million USD | -3674.501% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -5961.07% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -225.971% |
| IGM Biosciences, Inc. | 265.59 Million USD | -61.019% |
| INmune Bio, Inc. | 29.89 Million USD | -1330.462% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -147.836% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -960.792% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2576.271% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -2616.701% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -588.671% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -297.733% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -55.119% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -41.864% |
| Verastem, Inc. | 92.08 Million USD | -364.414% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -2283.918% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -130.26% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -252.246% |
| Histogen Inc. | 14.27 Million USD | -2896.434% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -2564.801% |
| Surrozen, Inc. | 18.55 Million USD | -2205.396% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2767.254% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8301.398% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -616.656% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1567.45% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -809.78% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -5502.775% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -140.07% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -782.702% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -74.549% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -2682.995% |
| Apollomics, Inc. | 54.14 Million USD | -689.898% |
| Amarin Corporation plc | 272.35 Million USD | -57.019% |
| Mesoblast Limited | 5.9 Million USD | -7145.866% |
| Turnstone Biologics Corp. | 78.33 Million USD | -445.905% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -75.179% |
| Synaptogenix, Inc. | 8.31 Million USD | -5043.836% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -2831.928% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -68.995% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1183.078% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -4742.482% |
| Exelixis, Inc. | 1.58 Billion USD | 73.049% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1017.691% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -84.293% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 49.994% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3521.993% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -5217.782% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -1325.836% |
| Gritstone bio, Inc. | 148.37 Million USD | -188.225% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -521.035% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -2513.969% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1545.065% |
| Insmed Incorporated | 949.26 Million USD | 54.949% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -2625.665% |
| MediWound Ltd. | 18.86 Million USD | -2166.541% |
| OmniAb, Inc. | 83.89 Million USD | -409.746% |
| Alector, Inc. | 248.8 Million USD | -71.884% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -82.517% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -718.455% |
| Zai Lab Limited | 547.47 Million USD | 21.887% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -7.274% |
| Aura Biosciences, Inc. | 84.99 Million USD | -403.172% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -73.041% |
| Immunic, Inc. | 99.22 Million USD | -331.0% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -168.943% |
| Veracyte, Inc. | 357.93 Million USD | -19.478% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 95.257% |
| FibroGen, Inc. | 398.11 Million USD | -7.42% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2909.507% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -6108.686% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -5901.503% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 86.864% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1552.885% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -35.1% |
| TG Therapeutics, Inc. | 198.47 Million USD | -115.468% |
| Galecto, Inc. | 35.62 Million USD | -1100.356% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -951.024% |
| Fortrea Holdings Inc. | 457.3 Million USD | 6.483% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -687.89% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1380.889% |
| XBiotech Inc. | 37.51 Million USD | -1040.099% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -521.035% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1971.049% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -201.033% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -331.644% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -286.259% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 55.372% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1382.583% |
| Vaxxinity, Inc. | 56.05 Million USD | -662.968% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 0.694% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1817.003% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -285.733% |
| NexImmune, Inc. | 28.16 Million USD | -1418.242% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -7631.966% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -2290.112% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 84.81% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1579.764% |
| Scopus BioPharma Inc. | 11.71 Million USD | -3550.495% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -236.569% |
| Ainos, Inc. | 12.95 Million USD | -3201.645% |
| Pluri Inc. | 22.48 Million USD | -1802.362% |
| Prothena Corporation plc | 282.4 Million USD | -51.431% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -113.802% |
| Celularity Inc. | 215.05 Million USD | -98.854% |
| Rallybio Corporation | 78.93 Million USD | -441.797% |
| Cue Biopharma, Inc. | 19.54 Million USD | -2088.369% |
| MeiraGTx Holdings plc | 151.07 Million USD | -183.066% |
| Omeros Corporation | 94.75 Million USD | -351.342% |
| Humacyte, Inc. | 23.49 Million USD | -1720.024% |
| Immunocore Holdings plc | 308.04 Million USD | -38.83% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -12515.074% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -392.317% |
| Blueprint Medicines Corporation | 722.86 Million USD | 40.839% |
| CalciMedica, Inc. | 21.81 Million USD | -1860.173% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -472.798% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -166.383% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -149.658% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -44.996% |
| Pulmatrix, Inc. | 22.03 Million USD | -1840.516% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -1136.879% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -381.231% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 22.466% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -489.449% |
| Cytokinetics, Incorporated | 173.61 Million USD | -146.326% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -1142.485% |
| Nutriband Inc. | 5.73 Million USD | -7358.122% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -880.559% |
| Vor Biopharma Inc. | 126.03 Million USD | -239.309% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 64.038% |
| Evogene Ltd. | 27.79 Million USD | -1438.866% |
| ProKidney Corp. | 151.52 Million USD | -182.237% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -476.543% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -5459.51% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 30.376% |
| CorMedix Inc. | 48.95 Million USD | -773.51% |
| BioLineRx Ltd. | 50.8 Million USD | -741.8% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -183.776% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1023.269% |
| Atai Life Sciences N.V. | 125.78 Million USD | -239.986% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -423.83% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -425.312% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -69.332% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1206.203% |
| MediciNova, Inc. | 10.9 Million USD | -3823.308% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -231.976% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -5790.896% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7001.274% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 10.225% |
| Biomea Fusion, Inc. | 126.13 Million USD | -239.042% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 67.401% |
| Mereo BioPharma Group plc | 35.84 Million USD | -1093.156% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -123.797% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -85.972% |
| Absci Corporation | 73.66 Million USD | -480.527% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1450.471% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -220.122% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -76.597% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -63.196% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -105.607% |
| Allakos Inc. | 196.05 Million USD | -118.127% |
| Imunon, Inc. | 20.31 Million USD | -2005.574% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -276.888% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -16.017% |
| BioAtla, Inc. | 129.68 Million USD | -229.756% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3521.993% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -2599.306% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -403.605% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -924.118% |
| XOMA Corporation | 46.46 Million USD | -820.412% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -284.679% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -200.184% |
| aTyr Pharma, Inc. | 12.97 Million USD | -3194.946% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -312.568% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -147.383% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -67.862% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1043.207% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -5099.522% |
| Akari Therapeutics, Plc | 16.8 Million USD | -2444.633% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -18706.361% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -42.875% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6255.598% |
| UroGen Pharma Ltd. | 138.88 Million USD | -207.911% |
| Sutro Biopharma, Inc. | 243 Million USD | -75.982% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -5778.67% |
| Orgenesis Inc. | 45.75 Million USD | -834.613% |
| Entera Bio Ltd. | 8.86 Million USD | -4726.761% |
| GH Research PLC | 41.22 Million USD | -937.434% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1563.494% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -414.913% |
| Xencor, Inc. | 306.97 Million USD | -39.31% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -8568.122% |
| Replimune Group, Inc. | 234.77 Million USD | -82.155% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1987.132% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -122.972% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6255.598% |
| Portage Biotech Inc. | 18.19 Million USD | -2249.86% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -5790.896% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -307.438% |
| OncoCyte Corporation | 25.63 Million USD | -1568.101% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -6915.725% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -3632.641% |
| Purple Biotech Ltd. | -22.46 Million USD | 2003.463% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -2494.97% |
| scPharmaceuticals Inc. | 65.17 Million USD | -556.128% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -4959.32% |
| HilleVax, Inc. | 133.34 Million USD | -220.71% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -4058.007% |
| Tharimmune, Inc. | 9.45 Million USD | -4422.909% |
| Genprex, Inc. | 31.06 Million USD | -1276.829% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -128.049% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1262.944% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -55802.092% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -7751.246% |
| OKYO Pharma Limited | 8243.57 USD | -5187591.74% |
| Savara Inc. | 15.74 Million USD | -2616.107% |
| Curis, Inc. | 58.35 Million USD | -632.844% |
| Daré Bioscience, Inc. | 33.6 Million USD | -1172.415% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -8297.683% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -5631.819% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1482.603% |
| BeiGene, Ltd. | 3.28 Billion USD | 86.988% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -2044.764% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 14.258% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -178.324% |
| Erasca, Inc. | 141.52 Million USD | -202.173% |
| bluebird bio, Inc. | 240.23 Million USD | -78.016% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9346.73% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 75.511% |
| DBV Technologies S.A. | 92.16 Million USD | -364.031% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9346.73% |
| Moderna, Inc. | 6.39 Billion USD | 93.312% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -903.664% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -2876.827% |
| Molecular Templates, Inc. | 63.09 Million USD | -577.832% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -541.146% |
| Travere Therapeutics, Inc. | 472 Million USD | 9.396% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -198.408% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -588.849% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -885.053% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -105.473% |
| MacroGenics, Inc. | 217.21 Million USD | -96.879% |
| RenovoRx, Inc. | 11.39 Million USD | -3652.641% |
| Adicet Bio, Inc. | 152.03 Million USD | -181.279% |
| Prime Medicine, Inc. | 186.63 Million USD | -129.133% |
| Aditxt, Inc. | 25.95 Million USD | -1547.932% |
| Adagene Inc. | 41.83 Million USD | -922.322% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5750.14% |
| Quantum-Si incorporated | 111.65 Million USD | -282.997% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -148.851% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -2833.584% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -1093.822% |
| SciSparc Ltd. | 9.01 Million USD | -4645.877% |
| Vericel Corporation | 142.04 Million USD | -201.078% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4840.136% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1752.218% |
| Generation Bio Co. | 144.46 Million USD | -196.02% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -415.056% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -394.623% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -44.613% |
| Invivyd, Inc. | 205.75 Million USD | -107.845% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -492.651% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -4459.906% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -468.277% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -4057.198% |
| 2seventy bio, Inc. | 289.88 Million USD | -47.523% |
| ADMA Biologics, Inc. | 66.58 Million USD | -542.254% |
| Clene Inc. | 41.07 Million USD | -941.197% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -3238.966% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -680.442% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7001.274% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -21.475% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -1064.246% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -1167.941% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -312.385% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -1212.256% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -151.149% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 44.296% |
| Evaxion Biotech A/S | 22.27 Million USD | -1820.301% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -215.507% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -82.071% |
| Trevena, Inc. | 38.41 Million USD | -1013.298% |
| Surrozen, Inc. | 18.55 Million USD | -2205.396% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -434.932% |
| Cingulate Inc. | 22.75 Million USD | -1779.026% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 5808.102% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -857.42% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -5093.758% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -316.985% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 43.289% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -588.937% |
| Clearmind Medicine Inc. | 8.74 Million USD | -4792.276% |
| Kronos Bio, Inc. | 128.11 Million USD | -233.795% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -408.672% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -14480.743% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -324.143% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1383.38% |
| ImmunityBio, Inc. | 362.87 Million USD | -17.852% |
| Korro Bio, Inc. | 84.53 Million USD | -405.892% |
| Kineta, Inc. | 21.15 Million USD | -1921.417% |
| BioVie Inc. | 31.95 Million USD | -1238.492% |
| Codexis, Inc. | 66.51 Million USD | -542.91% |
| Celularity Inc. | 215.05 Million USD | -98.854% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -88.708% |
| Celcuity Inc. | 66.23 Million USD | -545.703% |
| Virax Biolabs Group Limited | 6.54 Million USD | -6431.952% |
| Cibus, Inc. | 320.3 Million USD | -33.514% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -894.537% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1163.595% |
| IN8bio, Inc. | 30.33 Million USD | -1309.668% |
| Kodiak Sciences Inc. | 277.32 Million USD | -54.208% |
| Annexon, Inc. | 143.72 Million USD | -197.552% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -235.173% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1766.738% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -66720.469% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 45.144% |
| Eyenovia, Inc. | 25.4 Million USD | -1583.238% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -204.779% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -7588.799% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -440.421% |
| Arcellx, Inc. | 200.19 Million USD | -113.613% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -831.702% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -97.611% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -4194.978% |
| Moolec Science SA | 52.75 Million USD | -710.703% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -599.485% |
| Geron Corporation | 70.44 Million USD | -507.105% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -818.889% |
| Royalty Pharma plc | 862.4 Million USD | 50.412% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -354.6% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -4484.661% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1789.875% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -105.787% |
| Humacyte, Inc. | 23.49 Million USD | -1720.024% |
| Structure Therapeutics Inc. | 102.77 Million USD | -316.104% |
| 89bio, Inc. | 151.2 Million USD | -182.83% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -433.683% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -2841.204% |
| Genelux Corporation | 24.33 Million USD | -1657.349% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -1160.652% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -147.384% |
| Notable Labs, Ltd. | 14.77 Million USD | -2795.403% |
| Liquidia Corporation | 87.98 Million USD | -386.055% |
| Mustang Bio, Inc. | 48.5 Million USD | -781.736% |
| Immunovant, Inc. | 282.7 Million USD | -51.269% |
| Quantum-Si incorporated | 111.65 Million USD | -282.997% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1796.961% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1910.867% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -319.216% |
| Acasti Pharma Inc. | 11.3 Million USD | -3684.187% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1765.752% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2576.271% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -818.85% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -37592.45% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -2591.999% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1366.718% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -933.373% |
| PepGen Inc. | 84.76 Million USD | -404.508% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1343.255% |
| United Therapeutics Corporation | 885.1 Million USD | 51.683% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1767.716% |
| Solid Biosciences Inc. | 104.31 Million USD | -309.961% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1206.781% |
| Immuneering Corporation | 58.41 Million USD | -632.118% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8301.398% |
| Silo Pharma, Inc. | 3.92 Million USD | -10804.301% |
| Belite Bio, Inc | 31.66 Million USD | -1250.42% |
| XOMA Corporation | 46.46 Million USD | -820.412% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -533.088% |
| Bionomics Limited | 17.89 Billion USD | 97.61% |
| Apogee Therapeutics, Inc. | 93 Million USD | -359.825% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1298.573% |
| uniQure N.V. | 285.08 Million USD | -50.008% |
| Cassava Sciences, Inc. | 105.95 Million USD | -303.608% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5750.14% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -120.204% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1216.781% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -5046.993% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1354.843% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -7588.799% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2909.507% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -4711.014% |
| Altimmune, Inc. | 30.55 Million USD | -1299.565% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1298.573% |
| Compugen Ltd. | 43.97 Million USD | -872.575% |
| Peak Bio, Inc. | 1249.13 USD | -34235808.192% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -476.971% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1810.692% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -75.851% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1398.269% |
| Zura Bio Limited | 62.63 Million USD | -582.734% |
| PolyPid Ltd. | 21.04 Million USD | -1932.079% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -2527.494% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1398.269% |
| Instil Bio, Inc. | 85.78 Million USD | -398.515% |
| argenx SE | 1.53 Billion USD | 72.113% |
| Immunome, Inc. | 122.82 Million USD | -248.193% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -782.246% |
| Verona Pharma plc | 67.15 Million USD | -536.847% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1552.119% |
| Shattuck Labs, Inc. | 93.61 Million USD | -356.824% |
| CervoMed Inc. | 14.95 Million USD | -2759.056% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -504.856% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -4905.279% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -738.531% |
| Moolec Science SA | 52.75 Million USD | -710.703% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -2499.949% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -222.621% |
| AnaptysBio, Inc. | 181.56 Million USD | -135.532% |
| Design Therapeutics, Inc. | 78.19 Million USD | -446.938% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -391.321% |
| NeurAxis, Inc. | 8.82 Million USD | -4747.992% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -3298.101% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1006.042% |
| Achilles Therapeutics plc | 75.25 Million USD | -468.269% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1552.119% |
| 180 Life Sciences Corp. | 13.47 Million USD | -3073.074% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1513.629% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -14480.743% |
| Nutriband Inc. | 5.73 Million USD | -7358.122% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -286.036% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -668.424% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -740.526% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -546.986% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -690.145% |
| Palisade Bio, Inc. | 13.32 Million USD | -3110.593% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -841.776% |
| Beam Therapeutics Inc. | 554.19 Million USD | 22.834% |
| Neurogene Inc. | 55.58 Million USD | -669.392% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -72.101% |
| AEON Biopharma, Inc. | 48.42 Million USD | -783.047% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -342.199% |
| Sesen Bio, Inc. | 78.38 Million USD | -445.605% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -411.979% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -3297.589% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 5.176% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -386.575% |
| Athira Pharma, Inc. | 125.46 Million USD | -240.85% |
| Vaccinex, Inc. | 23.45 Million USD | -1723.283% |
| HCW Biologics Inc. | 21.02 Million USD | -1933.768% |
| XOMA Corporation | 46.46 Million USD | -820.412% |
| Nektar Therapeutics | 190.9 Million USD | -124.015% |
| Arvinas, Inc. | 480 Million USD | 10.906% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -18706.361% |
| Merus N.V. | 200.49 Million USD | -113.299% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -313.769% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -1135.272% |
| Rezolute, Inc. | 70.38 Million USD | -507.571% |
| Clene Inc. | 41.07 Million USD | -941.197% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -2511.055% |
| BeyondSpring Inc. | 24.86 Million USD | -1619.891% |
| Synlogic, Inc. | 58.53 Million USD | -630.628% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -2290.18% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -9420.28% |
| Peak Bio, Inc. | 1249.13 USD | -34235808.192% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -607.493% |
| Krystal Biotech, Inc. | 160.42 Million USD | -166.572% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -58.02% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -22.875% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -19728.639% |
| MannKind Corporation | 125.59 Million USD | -240.495% |
| Ikena Oncology, Inc. | 84.57 Million USD | -405.635% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -4332.995% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -377.284% |
| Gossamer Bio, Inc. | 183.75 Million USD | -132.724% |
| CohBar, Inc. | 12.38 Million USD | -3352.056% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -743.094% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1450.471% |
| Legend Biotech Corporation | 583.14 Million USD | 26.665% |
| Mural Oncology plc | 192.07 Million USD | -122.653% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -536.888% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -2548.769% |
| Disc Medicine, Inc. | 91.12 Million USD | -369.302% |
| Champions Oncology, Inc. | 28.11 Million USD | -1421.348% |
| REGENXBIO Inc. | 321.15 Million USD | -33.159% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -7876.727% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -667.004% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -997.649% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -273.961% |
| Vaxart, Inc. | 90.72 Million USD | -371.365% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -4919.373% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -899.323% |
| Cellectis S.A. | 97.32 Million USD | -339.428% |
| Longeveron Inc. | 21.25 Million USD | -1912.475% |
| Repare Therapeutics Inc. | 167.35 Million USD | -155.532% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 68.574% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -465.339% |
| Revolution Medicines, Inc. | 498.76 Million USD | 14.258% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -6328.909% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -872.951% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -473.336% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -514.132% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -3766.646% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 91.044% |
| Denali Therapeutics Inc. | 527.23 Million USD | 18.887% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4840.136% |
| Veru Inc. | 101.34 Million USD | -321.962% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1727.022% |
| Cingulate Inc. | 22.75 Million USD | -1779.026% |
| Passage Bio, Inc. | 108.38 Million USD | -294.552% |
| Context Therapeutics Inc. | 25.07 Million USD | -1605.65% |
| Exicure, Inc. | 14.07 Million USD | -2938.157% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -107.533% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -887.624% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -4559.883% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -69.378% |
| Nuvalent, Inc. | 149.49 Million USD | -186.069% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -5201.304% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -312.591% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1893.804% |
| OmniAb, Inc. | 83.89 Million USD | -409.746% |
| Anew Medical, Inc. | 1.3 Million USD | -32774.963% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1205.247% |
| Lipocine Inc. | 15.08 Million USD | -2735.856% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -524.19% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -461.576% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -960.792% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -272.379% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1810.521% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 35.609% |
| Ocugen, Inc. | 71.56 Million USD | -497.553% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -355.597% |
| Q32 Bio Inc. | 92.68 Million USD | -361.427% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1919.699% |
| Alumis Inc. Common Stock | 158.17 Million USD | -170.367% |
| Equillium, Inc. | 50.6 Million USD | -745.06% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -585.272% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -2975.397% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -2166.889% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -810.845% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -294.272% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -3350.822% |
| Dominari Holdings Inc. | 23.83 Million USD | -1694.214% |
| Edesa Biotech, Inc. | 9.22 Million USD | -4536.91% |
| vTv Therapeutics Inc. | 11.9 Million USD | -3491.593% |
| Bio-Techne Corporation | 563.03 Million USD | 24.046% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -4.61% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -59.122% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -223.3% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -2867.532% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -161.247% |
| Nkarta, Inc. | 131.65 Million USD | -224.839% |
| BioCardia, Inc. | 12.12 Million USD | -3428.182% |
| Iterum Therapeutics plc | 47.46 Million USD | -800.925% |